Hepatitis C Therapy - SciClone Reports Results From First ZADAXIN Phase 3 Hepatitis C Trial

SciClone Reports Results From First ZADAXIN Phase 3 Hepatitis C Trial
Market Wire - SAN MATEO, CA -- (MARKET WIRE) -- 12/14/2005 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN ) today announced top-line results from the first of its two phase 3 clinical trials using ZADAXIN (thymalfasin) in combination with pegylated interferon

Anadys travels a different path
SignOn San Diego - In a heady year for patients seeking significant advances in the treatment of hepatitis C, San Diego's Anadys Pharmaceuticals has been not so much overlooked as overshadowed. Most of the attention has focused on biotech companies developing new drugs